Synthesis and antiproliferative activities against Hep-G2 of salicylanide derivatives: potent inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase

References

• Burkhart DJ, Barthel BL, Post GC, Kalet BT, Nafie JW, Shoemaker RK, Koch TH. Design, synthesis, and preliminary evaluation of doxazolidine carbamates as prodrugs activated by carboxylesterases. J Med Chem 2006;49:7002–7012.
   PubMed Web of Science ®Google Scholar
• Ksander GM, de Jesus R, Yuan A, Fink C, Moskal M, Carlson E, Kukkola P, Bilci N, Wallace E, Neubert A, Feldman D, Mogelesky T, Poirier K, Jeune M, Steele R, Wasvery J, Stephan Z, Cahill E, Webb R, Navarrete A, Lee W, Gibson J, Alexander N, Sharif H, Hospattankar A. Diaminoindanes as microsomal triglyceride transfer protein inhibitors. J Med Chem 2001;44:4677–4687.
   PubMed Web of Science ®Google Scholar
• Ou TM, Lu YJ, Zhang C, Huang ZS, Wang XD, Tan JH, Chen Y, Ma DL, Wong KY, Tang JCO, Chan ASC, Gu LQ. Stabilization of G-quadruplex DNA and down-regulation of oncogene c-myc by quindoline derivatives. J Med Chem 2007;50:1465–1474.
   PubMed Web of Science ®Google Scholar
• Hsieh PW, Chang FR, Wu CC, Wu KY, Li CM, Chen SL, Wu YC. New cytotoxic cyclic peptides and dianthramide from Dianthus superbus. J Nat Prod 2004;67:1522–1527.
   PubMed Web of Science ®Google Scholar
• Fry DW, Kraker AJ, McMichael A, Ambroso LA, Nelson JM, Leopold WR, Connors RW, Bridges AJ. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 1994;265:1093–1995.
   PubMed Web of Science ®Google Scholar
• Ward WHJ, Cook PN, Slater AM, Davies DH, Holdgate GA, Green LR. Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure based searching and discovery of a potent inhibitor. Biochem Pharmacol 1994;48:659–666.
   PubMed Web of Science ®Google Scholar
• Tsou HR, Mamuya N, Johnson BD, Reich MF, Gruber BC, Ye F, Nilakantan R, Shen R, Discafani C, DeBlanc R, Davis R, Koehn FE, Greenberger LM, Wang YF, Wissner A. 6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity. J Med Chem 2001;44:2719–2734.
   PubMed Web of Science ®Google Scholar
• Bridges AJ, Zhou H, Cody DR, Rewcastle GW, McMichael A, Showalter HDH, Fry DW, Kraker AJ, Denny W. Tyrosine kinase inhibitors 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth receptor. J Med Chem 1996;39:267–276.
   PubMed Web of Science ®Google Scholar
• Domarkas J, Dudouit F, Williams C, Qiyu Q, Banerjee R, Brahimi F, Jean-Claude BJ. The combi-targeting concept: synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor rceptor (EGFR). J Med Chem 2006;49:3544–3552.
   PubMed Web of Science ®Google Scholar
• Kamath S, Buolamwini JK. Receptor-guided alignment-based comparative 3D-QSAR studies of benzylidene malonitrile tyrphostins as EGFR and HER-2 kinase inhibitors. J Med Chem 2003;46:4657–4668.
   PubMed Web of Science ®Google Scholar
• Brahimi F, Matheson SL, Dudouit F, McNamee JP, Tari AM, Jean-Claude BJ. Inhibition of epidermal growth factor receptor.mediated signaling by “combi-triazene” BJ2000, a new probe for combi-targeting postulates. J Pharmacol Exp Ther 2002;303:238–246.
   PubMedGoogle Scholar
• Matheson SL, McNamee J, Jean-Claude BJ. Design of a chimeric 3-methyl-1,2,3-triazene with mixed receptor tyrosine kinase and DNA damaging properties: a novel tumor targeting strategy. J Pharmacol Exp Ther 2001;296:832–840.
   PubMedGoogle Scholar
• Hickey K, Grehan D, Reid IM, O’Briain S, Walsh TN, Hennessy TPJ. Expression of epidermal growth-factor receptor and proliferating cell nuclear antigen predicts response of neophageal squamous-cell carcinoma to chemoradiotherapy. Cancer 1994;74:1693–1698.
   PubMedGoogle Scholar
• Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Mol Cell Biol 2001;2:127–137.
   Google Scholar
• Hynes NE, Stern DF. The biology of ErbB-2 neu her-2 and its role in cancer. Biochim Biophys Acta 1994;1198:165–184.
   PubMed Web of Science ®Google Scholar
• Gullick WJ. Prevalence of aberrant expression of the epidermal growth-factor receptor in human cancers. Br Med Bull 1991;47:87–98.
   PubMed Web of Science ®Google Scholar
• Moscatello DK, Holgado-Mudruga M, Godwin AK, Ramirez G, Gunn G, Zoltick PW, Biegel JA, Hayes RL, Wong AJ. Frequent expression of a mutant epidermal growth-factor receptor in multiple human tumors. Cancer Res 1995;55:5536–5539.
   PubMed Web of Science ®Google Scholar
• Wikstrand CJ, McLendon RE, Friedman A, Bigner DD. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res 1997;57:4130–4140.
   PubMed Web of Science ®Google Scholar
• Bridges AJ. The rationale and strategy used to develop a series of highly potent, irreversible, inhibitors of the epidermal growth factor receptor family of tyrosine kinases. Curr Med Chem 1999;6:825–843.
   PubMed Web of Science ®Google Scholar
• Boschelli DH. Small molecule inhibitors of receptor tyrosine kinases. Drugs Future 1999;24:515–537.
   Google Scholar
• Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 1998;19:1639–1662.
   Web of Science ®Google Scholar
• Goodsell DS, Morris GM, Olson AJ, Automated docking of flexible ligands: applications of AutoDock. J. Mol. Recognit. 1996;9,1–5.
   PubMed Web of Science ®Google Scholar
• Huey R, Morris GM, Olson AJ, Goodsell DS. A semiempirical free energy force field with charge-based desolvation. J Comput Chem 2007;28:1145–1152.
   PubMed Web of Science ®Google Scholar
• Pless SA, Millen KS, Hanek AP, Lynch JW, Lester HA, Lummis SCR, Dougherty DA. A cation-pi interaction in the binding site of the glycine receptor is mediated by a phenylalanine residue. J Neurosci 2008;28:10937–10942.
   PubMed Web of Science ®Google Scholar
• Xiao ZP, Li HQ, Shi L, Lv PC, Song ZC, Zhua HL. Synthesis, antiproliferative activity, and structure-activity relationships of 3-aryl-1H-quinolin-4-ones. Chem Med Chem 2008;3:1077–1082.
   Google Scholar
• Tsou HR, Mamuya N, Johnson BD, Reich MF, Gruber BC, Ye F, Nilakantan R, Shen R, Discafani C, DeBlanc R, Davis R, Koehn FE, Greenberger LM, Wang YF, Wissner A. 6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity. J Med Chem 2001;44:2719–2734.
   PubMed Web of Science ®Google Scholar